[Clinical application of microarray technique to quantify the lamivudine-resistant gene mutant of hepatitis B virus].
OBJECTIVE
To evaluate clinical applicability of a novel technique that can quantify the lamivudine-resistant mutants of hepatitis B virus (HBV) in the serum of patients utilizing gene microarray technology.


METHODS
The oligonucleotide microarray was designed to detect 3 important mutational positions. Fifty-one patients who were receiving lamivudine therapy were selected as subjects. The oligonucleotide microarray and traditional sequencing were applied to detect the lamivudine resistant mutation, the monitoring lasted for 24 months. Then the clinical result was analyzed and the obtained data were compared between the two methods.


RESULTS
Lamivudine resistant mutation was detected in 39 percent of the patients during the 2 years period. The results of the oligonucleotide microarray technique was consistent to the results of traditional sequencing in accuracy and the miroarray was more sensitive in detection of the mixed infection.


CONCLUSIONS
Application of the oligonucleotide microarray for quantitative detection of lamivudine-resistant mutation of HBV is feasible.
Huang
Xi-tian
XT
The Affinited Wenling Hospital of Wenzhou Medical College, Wenling 317500, China.
Zeng
Ai-ping
AP
Lin
Feng
F
D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*
D000998:Antiviral Agents; D019259:Lamivudine